Antisoma will choose up to three compounds from the EcoBiotics portfolio to evaluate during the next year. If these evaluations yield positive results, Antisoma will have rights to license up to two of the compounds for development as anticancer drugs on pre-agreed terms.
EcoBiotics has a diverse portfolio of structurally defined and patent-protected molecules derived from tropical rainforest plants. A number of these molecules have already demonstrated anticancer activity in early preclinical assessments. All those evaluated by Antisoma will be small molecules that can be made by chemical synthesis.
“There is a natural synergy between the discovery expertise of EcoBiotics and the development capabilities of Antisoma that provides the opportunity for rapid advancement of molecules that show potential as oncology drugs,” said EcoBiotics CEO, Dr Victoria Gordon.